Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation: A Case Report

Takafumi Yorozuya; Mitsuo Otsuka; Shin Ichihara; Kento Fujimori; Chikako Kitamura; Tomoyuki Takahashi; Masaki Mori; Yasushi Cho; Hirofumi Chiba

doi:10.2169/internalmedicine.7623-21

This article has now been updated. Please use the final version.

Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation: A Case Report

Takafumi Yorozuya, Mitsuo Otsuka, Shin Ichihara, Kento Fujimori, Chikako Kitamura, Tomoyuki Takahashi, Masaki Mori, Yasushi Cho, Hirofumi Chiba

Author information

Keywords: thymus, thymic carcinoma, thymic adenocarcinoma, BRAF V600E, thyroid transcription factor-1

JOURNAL OPEN ACCESS Advance online publication

Article ID: 7623-21

DOI https://doi.org/10.2169/internalmedicine.7623-21

The final version of this article is now available: Vol. 61 (2022), No. 3 pp. 385-388

Details

Abstract

Thymic adenocarcinomas are rare. We herein report for the first time a case of thymic adenocarcinoma with positivity for thyroid transcription factor-1 (TTF-1) and a BRAF V600E mutation. A 50-year-old woman had persistent suffocation and chest pain. Computed tomography revealed a 42×28-mm tumor in the anterior mediastinum. The patient underwent tumor resection using video-assisted thoracoscopic surgery. Histopathological findings showed thymic papillary adenocarcinoma, Masaoka stage II. Immunohistochemically, the tumor was positive for TTF-1. A sequencing analysis revealed a BRAF V600E mutation. The patient underwent postoperative radiotherapy and was in good health without recurrence at five months after resection.

Corresponding author

Register with J-STAGE for free!